Youbetme is a patent pending consumer technology platform that allows nearly anyone, anywhere, anytime to place a bet with their friends. Their peer to peer social betting platform is the modern day handshake--it's not official until its on Youbetme! The company has secured $1,225,000 in Seed-level funding from angel investors and a New York based venture capital fund, OmegaGE. Raised for the purpose of initial marketing launch and ongoing programming development for a new service designed to revolutionize the social betting experience, Youbetme caters to sports enthusiasts, college students, young professionals, and anyone seeking a simple and engaging way to place a friendly wager on anything and everything. The native iOS app is currently available for download. Youbetme was co-founded by Jason Neubauer and Justin Jarman. The founding team also consists of CTO Nils Lahr, who was the lead architect and inventor of iBEAM Broadcasting, and current co-founder of Synergy Sports Technology. Followed by Andrew Arata who is the Senior VP of Business Development, and User Acquisition Expert Chris Hedgecock, founder of Zeropaid.com and Yumm.com. Not to mention a powerhouse advisory board including: Reed Shaffner former Zynga GM, Brad Klaus former CEO of Extole, and others. About Social Bet, Inc. Social Bet, Inc. is an Angel-funded startup seeking to bring a fun and unique experience to the social mobile gaming space. Designed to meet or exceed the expectations of a serious better, but fun enough for anyone, Youbetme offers validity and liquidity amongst friends—where the only thing you can lose is your credibility. Learn more at www.youbetme.com Youbetme is a trademark of Social Bet, Inc. All other trademarks and registered trademarks previously cited are the property of their respective owners and are hereby acknowledged.
EmboMedics, Inc. is a medical company focused on the development and commercialization of embolization materials, both drug-loaded and unloaded, for various medical conditions. The company offers products for treating uterine fibroid embolization, trauma, benign prostatic hyperplasia, and trans-arterial chemoembolization. In particular, its trans-arterial chemoembolization technique involves coating small particles with chemotherapy drugs, allowing for targeted blockage of blood supply to tumors while simultaneously delivering chemotherapy agents. Founded in 2012, EmboMedics is headquartered in Minnesota.